skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Treating acid reflux disease in patients with Down syndrome: pharmacological and physiological approaches

Review

(2006) Views  (518) Full article downloads

Authors: Francesco Macchini, Ernesto Leva, Maurizio Torricelli, et al

Published Date January 2011 Volume 2011:4 Pages 19 - 22
DOI: http://dx.doi.org/10.2147/CEG.S15872

Francesco Macchini, Ernesto Leva, Maurizio Torricelli, Alberto Valadè
Pediatric Surgery Unit, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy

Abstract: Down syndrome (DS) is often accompanied by gastrointestinal disease, occurring mainly in early infancy and frequently requiring therapy. Among motility disorders, the most frequent is gastroesophageal reflux disease (GERD), which may often be misdiagnosed because of its atypical manifestations. Early diagnosis of esophageal functional disorders is essential to prevent respiratory problems, growth retardation in children, weight loss in adults, and to establish the correct type of surgery if needed. Furthermore, the involvement of the enteric nervous system in the pathophysiology of GERD in DS is not yet completely understood but seems supported by much evidence. In fact DS is often associated with motor disorders and this evidence must be considered in the choice of therapy: in particular all options available to improve motility seem to be effective in these patients. The effectiveness of therapy is strictly related to the rate of mental impairment, so that modulating therapy is essential, especially in view of the severity of the neurological status.

Keywords: gastro-esophageal reflux disease, chromosome 21, Down syndrome






Readers of this article also read:

Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Infliximab therapy for moderately severe Crohn’s disease and ulcerative colitis: a retrospective comparison over 6 years
Management of achalasia
Enzyme replacement therapy for pancreatic insufficiency: present and future
Effects of a cellulose mask synthesized by a bacterium on facial skin characteristics and user satisfaction
Emerging treatment options for short bowel syndrome: potential role of teduglutide
New and emerging treatments for the prevention of recurrent diverticulitis
Infliximab to treat Crohn’s disease: an update
Evaluation of analgesic efficacy of bromfenac sodium ophthalmic solution 0.09% versus ketorolac tromethamine ophthalmic solution 0.5% following LASEK or Epi-LASIK
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio